Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Journal of Cancer

• Publication date

  2001-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0959-8049(01)00171-XPMID 11527683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study

  2004cited by this paper
• The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines

  2004cited by this paper
• Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

  2001cited by this paper
• Role of Formulation Vehicles in Taxane Pharmacology

  2001cited by this paper
• Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

  2000cited by this paper
• Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL

  2000cited by this paper
• Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients

  2000cited by this paper
• Measurement of fraction unbound paclitaxel in human plasma.

  2000cited by this paper
• Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids.

  1999cited by this paper
• Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

  1999cited by this paper
• Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL

  1999cited by this paper
• Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

  1999cited by this paper
• Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

  1999cited by this paper
• Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

  1998cited by this paper
• Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.

  1998cited by this paper
• Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

  1998cited by this paper
• Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review.

  1998cited by this paper
• Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

  1998cited by this paper
• Effects of Taxol on blood cells.

  1998cited by this paper
• Phase I trial of cremophor EL with bolus doxorubicin.

  1998cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997influential reference
• Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

  1997cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

  1997cited by this paper
• Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

  1997cited by this paper
• Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

  1997cited by this paper
• Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer

  1997cited by this paper
• Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

  1996cited by this paper
• Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

  1996cited by this paper
• Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.

  1996cited by this paper
• Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review

  1996cited by this paper
• Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

  1996cited by this paper
• Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models

  1996cited by this paper
• Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

  1996cited by this paper
• Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil.

  1995cited by this paper
• Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal.

  1995cited by this paper
• The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.

  1995cited by this paper
• Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.

  1995cited by this paper
• Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias.

  1995cited by this paper
• Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.

  1994cited by this paper
• Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

  1994cited by this paper
• The alteration of plasma lipoproteins by cremophor EL.

  1994cited by this paper
• Clinical relevance of P-glycoprotein expression in haematological malignancies.

  1994cited by this paper
• Potential neurotoxicity of the solvent vehicle for cyclosporine.

  1994cited by this paper
• European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

  1994cited by this paper
• Is Cremophor EL, solvent for paclitaxel, cytotoxic?

  1993cited by this paper
• Clinical toxicities encountered with paclitaxel (Taxol).

  1993cited by this paper
• Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance.

  1993cited by this paper
• Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line.

  1993cited by this paper
• Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

  1993cited by this paper
• Taxol: a history of pharmaceutical development and current pharmaceutical concerns.

  1993cited by this paper
• Reversal of multidrug resistance by surfactants.

  1992cited by this paper
• Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma.

  1992cited by this paper
• Sequences of taxol and cisplatin: a phase I and pharmacologic study.

  1991cited by this paper
• Cardiac disturbances during the administration of taxol.

  1991cited by this paper
• Interaction of cremophor EL with human plasma.

  1991cited by this paper
• Oncolytic effects of fatty acids in mice and rats.

  1991cited by this paper
• Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance.

  1991cited by this paper
• The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

  1990cited by this paper
• Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

  1990cited by this paper
• Hypersensitivity reactions from taxol.

  1990cited by this paper
• The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.

  1990cited by this paper
• Problems in therapeutic drug monitoring: free drug level monitoring.

  1988cited by this paper
• Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation.

  1988cited by this paper
• Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

  1987cited by this paper
• Cytotoxic effects of free fatty acids on ascites tumor cells.

  1987cited by this paper
• Central Nervous System Toxicity after Liver Transplantation

  1987cited by this paper
• Development of new anti-cancer drugs

  1986cited by this paper
• Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR).

  1980cited by this paper
• Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

  1977cited by this paper
• Unusual serum lipoprotein abnormality induced by the vehicle of miconazole.

  1977cited by this paper
• Adverse reactions to intravenous anaesthetic induction agents.

  1977cited by this paper
• Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin.

  1972cited by this paper
• Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

  1971cited by this paper

• Improved preparation of Abraxane® I.V. Infusion (paclitaxel nanoparticles).

  2026cites this paper
• Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization

  2026cites this paper
• The Current Landscape of Nanopaclitaxel Formulations and the Benefits of Polymeric Micellar Paclitaxel in Solid Tumors

  2026cites this paper
• Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.

  2026cites this paper
• Natural amphiphilic co-polymers as sustainable nanocarriers for enhanced solubility of hydrophobic drugs.

  2025cites this paper
• Strain-Dependent Neuronal Disposition and Toxicity of Paclitaxel in Mice

  2025cites this paper
• Polybasic nanogels for intracellular co-delivery of paclitaxel and carboplatin: a novel approach to ovarian cancer therapy

  2025cites this paper
• Advances in paclitaxel nanoformulations: A systematic review of in vivo therapeutic efficacy and safety enhancements.

  2025cites this paper
• Local Drug Delivery Systems for Cancer Therapy

  2025cites this paper
• Therapeutic Potential and Clinical Translation of Nanodrugs: A Path Forward- Case Studies from Bench to Bedside

  2025cites this paper
• Π-Π stacking stabilized polymeric micelles for hydrophobic drug delivery in the treatment of leishmaniasis.

  2025cites this paper
• Host-guest complexes of cucurbituril with the neutral guest valrubicin: an experimental and computational study

  2025influential citation
• Nanoparticles as Multifunctional Drug-Delivery Systems: A Comprehensive Review and Integration into Interventional Oncology.

  2025cites this paper
• Multicore, SDS-Based Polyelectrolyte Nanocapsules as Novel Nanocarriers for Paclitaxel to Reduce Cardiotoxicity by Protecting the Mitochondria

  2025cites this paper
• Drug Delivery System for the Anticancer Drug Paclitaxel Using Lipocalin-Type Prostaglandin D Synthase Conjugated to a Tumor-Targeting Peptide

  2025cites this paper
• Valine–Niclosamide for Treatment of Androgen Receptor Splice Variant-Positive Hepatocellular Carcinoma

  2025cites this paper
• Tailoring the Release of Paclitaxel from Electrospun Nonwovens

  2025cites this paper
• Engineering Nanoparticles for Gynecologic Cancer Therapy.

  2025cites this paper
• Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE

  2025cites this paper
• Improving the Treatment of Brain Gliomas Through Small-Particle-Size Paclitaxel-Loaded Micelles with a High Safety Profile

  2025cites this paper
• GSH-responsive paclitaxel prodrug used in chemotherapy in combination with photodynamic therapy.

  2025cites this paper
• Antitumor Efficacy of Paclitaxel Injection Concentrate for Nanodispersion in Patient-Derived Breast, Head and Neck, and Non-Small Cell Lung Cancer Mouse Xenografts

  2025cites this paper
• Therapeutic pancreatic cancer biomarkers and pharmacogenetics.

  2025cites this paper
• Adsorption and volumetric properties of berberine and its mixtures with nonionic surfactants of the Kolliphor type.

  2025cites this paper
• Investigation of 2,4 Di-tert-butylphenol Leaching from Multidose Ophthalmic Devices into Tacrolimus Micellar Formulations

  2025cites this paper
• Unveiling the peripheral nerve hallmarks of chemotherapy-induced neuropathy: insights from paclitaxel treatment in a murine model

  2025cites this paper
• Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer.

  2025cites this paper
• Development of Paclitaxel Injection Concentrate for Nanodispersion

  2025cites this paper
• Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies.

  2025cites this paper
• A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice

  2025cites this paper
• Bio-Based Hydrophobic Fiberglass Filters Functionalized with RPTES for Efficient Oil-Water Separation

  2025cites this paper
• A Micellar Nanoprobe for Fluorescence Image-Guided Delineation of Glioblastoma Margins.

  2025cites this paper
• Self-assembly of paclitaxel derivative and fructose as a potent inducer of immunogenic cell death to enhance cancer immunotherapy

  2025cites this paper
• Systemic delivery of sorafenib tosylate loaded LeciPlex®: A comparative assessment of nano assembly, biocompatibility, and In vivo drug disposition

  2025cites this paper
• Potent Therapeutic Efficacy of 9‐Bromo‐Noscapine Against Breast Cancer Cells Via Enhanced Bioavailability of the Noscapine‐Cyclodextrin Inclusion Complex

  2025cites this paper
• Surfactant–Particle Engineering Hybrids: Emerging Strategies for Enhancing Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs

  2025cites this paper
• The Application of Glycolipid-Type Microbial Biosurfactants as Active Pharmaceutical Ingredients for the Treatment and Prevention of Cancer

  2025cites this paper
• Programmable Nanostructure Assembly of a Paclitaxel Derivative Enables Tunable Anticancer Therapy via Hydrogen Bond Engineering

  2025cites this paper
• Design of paclitaxel-loaded PLGA nanoparticles assisted by compatibility modeling.

  2025cites this paper
• Isoamyloxy-substituted phthalocyanine complexes: Synthesis, solubilization and in vitro photodynamic activity

  2025cites this paper
• Synthesis and Characterization of Poly(Lactic-Co-Glycolic Acid)–Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models

  2025cites this paper
• Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer

  2025influential citation
• Synergistic efficacy and safety of PD-1/PD-L1 inhibitors combined with nab-paclitaxel and platinum chemotherapy in NSCLC: A systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Formation of water-in-water emulsions and microgels in nonionic surfactant + gelatin aqueous mixtures.

  2025cites this paper
• Preclinical Toxicity and Pharmacokinetic Evaluation of Paclitaxel Nanodispersion

  2025cites this paper
• “Nano-Paclitaxel” Unlocking Potential and Redefining Cancer Chemotherapy

  2025cites this paper
• The Potential of Amphiphilic Cyclodextrins as Carriers for Therapeutic Purposes: A Short Overview

  2025cites this paper
• Characterization and stability assessment of geraniol self-nanoemulsifying drug delivery systems (SNEDDS): A novel approach using dielectric spectroscopy

  2025cites this paper
• Inorganic nanoparticles as smart carriers for docetaxel delivery in cancer therapy: Mechanisms, targeting strategies, and translational insights

  2025cites this paper
• Nanoformulation-based drug delivery systems for the treatment of gastric cancer: recent developments and future prospects.

  2025cites this paper
• Nanofibers for paclitaxel delivery: A promising avenue for cancer therapy.

  2025cites this paper
• Macromolecular Diamidobenzimidazole Conjugates Can Activate Stimulator of Interferon Genes

  2025cites this paper
• An octupolar donor-acceptor dye exploiting aggregation-induced intersystem crossing for efficient ROS generation.

  2025cites this paper
• Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity

  2025cites this paper
• Enhanced oral bioavailability of paclitaxel amorphous solid dispersions by maximizing supersaturation

  2025cites this paper
• Liposomal formulations of novel metal-based complexes exhibiting high antitumor activity against melanoma.

  2025cites this paper
• Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol.

  2025cites this paper
• Chalcogen-bond engineered redox-responsive nano-prodrugs for anticancer therapy.

  2025cites this paper
• Hyaluronic acid-PPG-functionalized mesoporous silica nanoparticles facilitated paclitaxel's in vitro anticancer effects on MDA-MB-231 cells.

  2025cites this paper
• Permeation of Model Chemicals through Medical Gowns Used in Anticancer Drug Preparation.

  2025cites this paper
• MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation

  2025cites this paper
• Polyethylene glycol hexadecyl ether modified heparin for paclitaxel nano-delivery system

  2025cites this paper
• A Novel Self-Assembled Paclitaxel Nanodispersion Facilitates Rapid In-Vitro/In-Vivo Dissociation and Protein Binding

  2024cites this paper
• Toxicology study of a tissue anchoring paclitaxel prodrug

  2024cites this paper
• Nanotheranostics for gynecological cancers: a path forward for Africa

  2024cites this paper
• Combinatorial MD/QM studies to develop novel ionic liquid-based anticancer drug delivery systems with aminium derived from carbohydrates as cationic components

  2024cites this paper
• Synthesis, and antitumoral and antiviral evaluation of polyacetylene glycoside derivatives.

  2024cites this paper
• Peptide-Based Prodrug Approaches for Cancer Nanomedicine.

  2024cites this paper
• Synthesis and Characterization of N-Doped Carbon Quantum Dots and its Application for Efficient Delivery of Curcumin in Live Cell.

  2024cites this paper
• Tackling Biofilm Resistance of Gram-Positive and Gram-Negative Bacteria Against Levofloxacin via Nanotechnology and Essential Oils

  2024cites this paper
• Drug delivery process simulation—Quantifying the conformation dynamics of paclitaxel and cremophor EL

  2024cites this paper
• Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy

  2024cites this paper
• Evaluation of self-assembling properties of paclitaxel-biotin conjugates

  2024cites this paper
• Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics

  2024cites this paper
• Fabrication and evaluation of chitosan-coated nanostructured lipid carriers for co-delivery of paclitaxel and PD-L1 siRNA.

  2024cites this paper
• Paclitaxel prodrug nanoparticles boost antitumor efficacy via hitchhiking of human serum albumin.

  2024cites this paper
• Theranostic Diagnostics.

  2024cites this paper
• Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials

  2024cites this paper
• Effective paclitaxel: β-Cyclodextrin-based formulation boosts in vitro anti-tumor potential and lowers toxicity in zebrafish.

  2024cites this paper
• Controlled Delivery of Paclitaxel via Stable Synthetic Protein Nanoparticles

  2024cites this paper
• Near-Infrared Ratiometric Fluorescent Probe for Detecting Endogenous Cu2+ in the Brain.

  2024cites this paper
• Hemocompatible and biocompatible hybrid nanocarriers for enhanced oral bioavailability of paclitaxel: in vivo evaluation.

  2024cites this paper
• Paclitaxel Drug-Drug Interactions in the Military Health System.

  2024cites this paper
• Anti-Cancer Properties of Two Intravenously Administrable Curcumin Formulations as Evaluated in the 3D Patient-Derived Cancer Spheroid Model

  2024cites this paper
• Effect of sugar or sugar alcohol with different spatial structures on the stability of paclitaxel/HS15/Tween80 micelles: Based on micellization thermodynamics

  2024cites this paper
• Exploring chain length of modification module in disulfide bond bridged paclitaxel prodrug nanoassemblies for 4T1 breast tumor: The moderate is better.

  2024cites this paper
• Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

  2024cites this paper
• Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma

  2024cites this paper
• Breast cancer epidemiology, diagnostic barriers, and contemporary trends in breast nanotheranostics and mechanisms of targeting

  2024cites this paper
• Exosomes as novel nanocarriers for cancer therapy

  2024cites this paper
• Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity

  2024cites this paper
• The evolution of cyclosporine treatments for treatment of ocular surface diseases

  2024cites this paper
• Strategies in Taxol development. A review.

  2024cites this paper
• Evaluation of a mucoadhesive auto-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration.

  2024cites this paper
• Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples

  2024cites this paper
• Application of nano-radiosensitizers in non-small cell lung cancer

  2024cites this paper
• Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking

  2024cites this paper
• BIOSURFACTANTS: SUSTAINABLE ALTERNATIVE TO SYNTHETIC SURFACTANTS AND THEIR APPLICATIONS

  2024cites this paper
• Formulation and Evaluation of Idebenone Microemulsion as a Potential Approach for the Transmucosal Drug Delivery Systems

  2024cites this paper
• Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer

  2024cites this paper